Xanthine Compounds Targeting CUG Repeats for Myotonic Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for myotonic dystrophy types 1 and 2 are palliative and do not address the underlying disease effectively, lacking a definitive treatment to manage the multisystemic symptoms and pathogenesis.
Innovation Solution
The use of xanthine compounds, such as theophylline and its derivatives, which bind to CUG repeats, increasing the levels of free MBNL1 protein, thereby reducing the severity of symptoms by altering RNA splicing abnormalities and ribonuclear foci formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palliative therapeutic strategies are used for myotonic dystrophy, then symptom management is provided, but the underlying disease pathogenesis is not effectively addressed
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that bind to CUG repeat RNA sequences, acting as a mediator to release MBNL1 protein from sequestration. This intermediary approach allows the treatment to address the root cause (RNA-protein interaction) rather than just managing symptoms, resolving the contradiction between effective disease management and treatment definitiveness
Solution Approach 2:
The invention changes the molecular parameter of MBNL1 protein availability by introducing compounds that alter the binding equilibrium between MBNL1 and CUG repeats. This parameter change (increasing free MBNL1 levels) directly addresses the pathogenesis, transforming palliative care into a disease-modifying treatment
2Object-affected harmful factors
If MBNL1 protein is sequestered by CUG repeat RNA foci, then RNA splicing regulation is disrupted, but potential therapeutic targeting is created
Solution Approach 1:
The patent converts the harmful sequestration phenomenon into a beneficial therapeutic target. By designing compounds that compete for CUG repeat binding, the harmful MBNL1 sequestration is transformed into a reversible interaction that can be therapeutically modulated, turning the pathogenic mechanism into a treatment opportunity
Solution Approach 2:
Small molecule compounds serve as intermediaries that displace MBNL1 from CUG repeats without directly altering the RNA sequence or protein structure. This intermediary mechanism restores splicing regulation by competing for the same binding site, effectively reversing the harmful sequestration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The xanthine compounds effectively increase free MBNL1 protein levels, reducing ribonuclear foci and improving muscleblind protein expression, offering a potential therapeutic approach for myotonic dystrophy types 1 and 2 by targeting the root cause of RNA toxicity.
Implementation Method 1
xanthine compounds, such as theophylline and its derivatives, which bind to CUG repeats, increasing the levels of free MBNL1 protein
Data Source
AI summary
The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).